HIV news

At EACS 2023, we asked Professor Jürgen Rockstroh from the governing board of the European AIDS Clinical Society, about his highlights from the conference.

At EACS 2023, Dr Luis Sagaon-Teyssier from Institut de Recherche pour le Développement spoke to NAM aidsmap's Roger Pebody about drug-reduced strategies at one of Paris's largest HIV clinics.

At EACS 2023, Kevin Moody from the University of Amsterdam spoke to NAM aidsmap's Roger Pebody about post-traumatic stress disorder and HIV.

At EACS 2023, Olga Gvozdetska, acting Deputy Director General of the Ukrainian Public Health Center, spoke to NAM aidsmap's Roger Pebody about HIV services during the war in Ukraine.

At EACS 2023, Dr Raquel Martin Iguacel talks to NAM aidsmap's Roger Pebody about COVID-19 and the risk of cardiovascular disease in people with HIV.

At IAS 2023, Immaculate Owomugisha from the International Community of Women Living with HIV and Dr Carrie Lyons from the Johns Hopkins School of Public Health spoke to NAM aidsmap's Krishen Samuel about coercive reproductive healthcare practices reported by women with HIV. 

At IAS 2023, aidsmap's Krishen Samuel spoke to the US Ambassador to Uganda, Natalie Brown, and Dr Vamsi Vasireddy, who leads PEPFAR programmes in Uganda, about services for key populations in Uganda following the Anti-Homosexuality Act.

At IAS 2023, Dr Andrew Hill from the University of Liverpool talks to NAM aidsmap's Roger Pebody about adherence counselling reversing viral rebound on dolutegravir.

At IAS 2023, Dr Anthony Smith from the University of New South Wales spoke to NAM aidsmap's Krishen Samuel about the impact of mpox. 

At IAS 2023, Professor Francois Venter from Ezintsha, Johannesburg, spoke to NAM aidsmap's Roger Pebody about antiretrovirals and high blood pressure.

At IAS 2023, Professor Steven Grinspoon from Harvard Medical School spoke to NAM aidsmap's Roger Pebody about the use of statins in people living with HIV.

At IAS 2023, Dr Lara Vojnov from the World Health Organization (WHO) spoke to NAM aidsmap's Roger Pebody about viral load measurements and their relevance to transmission and WHO's statement on undetectable viral load.

At IAS 2023, Dr Asier Sáez-Cirión from the Institut Pasteur spoke to NAM aidsmap's Roger Pebody about HIV remission after a stem cell transplant. 

At CROI 2023, Professor Alessandro Grattoni from Houston Methodist Hospital spoke to NAM's Roger Pebody about an islatravir implant for PrEP.

 At CROI 2023, Professor Joseph Eron from University of North Carolina spoke to NAM's Roger Pebody about lenacapavir and two broadly neutralising antibodies for treatment.

At CROI 2023, Professor Chloe Orkin from Queen Mary University of London spoke to NAM's Roger Pebody about mpox in people with low CD4 counts.

At CROI 2023, Dr Bernard Surial from the University of Bern spoke to NAM's Roger Pebody about integrase inhibitors and cardiovascular disease.

At CROI 2023, Professor Annie Luetkemeyer from the University of California, San Francisco spoke with Liz Highleyman about doxyPEP and resistance.

At CROI 2023, Dr Jenell Stewart from the University of Washington spoke to NAM's Roger Pebody about doxyPEP for women.

At HIV Glasgpw 2022, Dr Miłosz Parczewski, President of the Polish AIDS Society, spoke to Roger Pebody about HIV care for Ukrainian refugees in Poland. 

At HIV Glasgow 2022, Professor Chloe Orkin, from Queen Mary University London, spoke to Roger Pebody about who is at risk of injectable treatment failure.

Dr Robin Lennon-Dearing from the University of Memphis talks to Mariah Wilberg about HIV criminalisation in Tennessee.

At AIDS 2022, Professor Lucie Cluver from the University of Cape Town talks to NAM's Roger Pebody about violence and HIV.

At AIDS 2022, Dr Jana Dickter talks about the 'City of Hope patient', a man from California who appears to have been cured of HIV after a stem cell transplant.

At AIDS 2022, Professor Annie Luetkemeyer and Professor Connie Celum talk about taking antibiotics (doxycycline) to prevent STIs.

At AIDS 2022, Dr Núria Climent & Dr José Alcamí from Hospital Clínic de Barcelona talk about a woman in Barcelona who has maintained an undetectable HIV viral load for more than 15 years after stopping antiretroviral therapy.

At the British HIV Association (BHIVA) conference, Dr Kate Childs from King's College Hospital, London talks to NAM aidsmap's Roger Pebody about the study she presented on loss to follow-up in south London clinics.

At CROI 2022, Professor Joel Palefsky from the University of California San Francisco talks about the ANCHOR trial, which has showed that screening and early treatment reduces anal cancer in people with HIV.

Dr Roger Shapiro from Harvard University talks about antibody treatment for children with HIV and could it be used instead of pills at CROI 2022.

At CROI 2022, Professor Yvonne Bryson from the University of California Los Angeles talks about the woman in New York who has no detectable HIV 14 months after stopping antiretroviral therapy following a stem-cell transplant for leukaemia.

Elena Vovc from the World Health Organization talks about the COVID-19 pandemic and how it has impacted HIV diagnoses, treatment and prevention. Elena presented these findings at a session at the EACS 2021 conference.

A new study shows that people with HIV with CD4 counts below 200 produce weaker responses to COVID-19 vaccines than people with better immune function. Dr Andrea Antinori of the National Institute for Infectious Diseases, Italy, talks about the research presented to the EACS 2021 conference.

NAM aidsmap's Susan Cole gives the keynote address of the closing session of the IAS 2021 conference: 'How do we continue to unite policy, science and activism in an increasingly fragmented world?'

At IAS 2021, Dr Maggie Czarnogorski of ViiV Healthcare talks about providing injectable HIV treatment.

Dr Lulu Nair of Stellenbosch University in Cape Town talks about vaginal rings and oral pre-exposure prophylaxis (PrEP) at IAS 2021.

Dr Silvia Bertagnolio of the World Health Organization talks about COVID-19 in people living with HIV at IAS 2021.

Professor Jean-Michel Molina of Hôpital Saint-Louis in Paris talks about injectable lenacapavir, a capsid inhibitor currently under development, for people with multidrug-resistant HIV at IAS 2021.

At IAS 2021, Professor Samir Gupta of Indiana University talks about lenacapavir, an experimental capsid inhibitor, for people starting HIV treatment.

A vaginal ring containing the anti-HIV medication dapivirine provides a new HIV prevention option for women. Dr Zeda Rosenburg from the International Partnership for Microbicides tells us about the ring being approved by regulators and plans for its roll-out in sub-Saharan Africa.

According to a report presented at the AIDS 2020 conference, a man in São Paulo had no evidence of remaining HIV after more than 15 months off antiretrovirals. Dr Andrea Savarino from the Instituto Superiore di Sanita in Rome talks to NAM aidsmap.

Our HIV Community Forum shared information on HIV treatment and prevention from the 9th IAS Conference on HIV Science. With Dr Tristan Barber, from Chelsea and Westminster NHS Foundation Trust; Memory Sachikonye, from UK Community Advisory Board (UK-CAB); and Gus Cairns and Roger Pebody, from NAM aidsmap.